JP2011507933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507933A5 JP2011507933A5 JP2010540130A JP2010540130A JP2011507933A5 JP 2011507933 A5 JP2011507933 A5 JP 2011507933A5 JP 2010540130 A JP2010540130 A JP 2010540130A JP 2010540130 A JP2010540130 A JP 2010540130A JP 2011507933 A5 JP2011507933 A5 JP 2011507933A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- targeting agent
- use according
- cell
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 40
- 230000008685 targeting Effects 0.000 claims 35
- 239000000427 antigen Substances 0.000 claims 31
- 102000036639 antigens Human genes 0.000 claims 31
- 108091007433 antigens Proteins 0.000 claims 31
- 239000003795 chemical substances by application Substances 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000012636 effector Substances 0.000 claims 5
- 230000009919 sequestration Effects 0.000 claims 5
- 239000003463 adsorbent Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 229940127121 immunoconjugate Drugs 0.000 claims 3
- 229940124549 vasodilator Drugs 0.000 claims 3
- 239000003071 vasodilator agent Substances 0.000 claims 3
- 210000000601 blood cell Anatomy 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229960001389 doxazosin Drugs 0.000 claims 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960001289 prazosin Drugs 0.000 claims 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims 2
- 229960001693 terazosin Drugs 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000002616 plasmapheresis Methods 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1663007P | 2007-12-26 | 2007-12-26 | |
| US1661307P | 2007-12-26 | 2007-12-26 | |
| PCT/EP2008/068268 WO2009080831A1 (en) | 2007-12-26 | 2008-12-23 | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014241327A Division JP2015038158A (ja) | 2007-12-26 | 2014-11-28 | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507933A JP2011507933A (ja) | 2011-03-10 |
| JP2011507933A5 true JP2011507933A5 (OSRAM) | 2012-02-16 |
Family
ID=40459778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540130A Pending JP2011507933A (ja) | 2007-12-26 | 2008-12-23 | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
| JP2014241327A Pending JP2015038158A (ja) | 2007-12-26 | 2014-11-28 | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014241327A Pending JP2015038158A (ja) | 2007-12-26 | 2014-11-28 | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9011864B2 (OSRAM) |
| EP (1) | EP2238169A1 (OSRAM) |
| JP (2) | JP2011507933A (OSRAM) |
| AR (1) | AR069979A1 (OSRAM) |
| TW (1) | TWI524897B (OSRAM) |
| WO (1) | WO2009080831A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| US9221914B2 (en) * | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
| JP5817034B2 (ja) * | 2007-12-26 | 2015-11-18 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体及びその使用 |
| BRPI0821417A2 (pt) * | 2007-12-26 | 2015-06-16 | Biotest Ag | Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo |
| AU2010244428B2 (en) | 2009-05-06 | 2015-01-29 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| AU2013201618B2 (en) * | 2009-05-06 | 2016-06-02 | Biotest Ag | Uses of immunoconjugates targeting CD138 |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| CA2858133A1 (en) | 2011-12-08 | 2013-06-13 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| EP2964753B1 (en) * | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| CN107708741A (zh) * | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| JP7350313B2 (ja) | 2016-12-16 | 2023-09-26 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| MY205689A (en) | 2017-10-02 | 2024-11-06 | Visterra Inc | Antibody molecules to cd138 and uses thereof |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
| CN113853217A (zh) * | 2019-04-29 | 2021-12-28 | 伊缪诺金公司 | 包含抗cd123免疫缀合物的治疗组合 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US12338291B2 (en) | 2019-06-17 | 2025-06-24 | Visterra, Inc. | Humanized antibody molecules to CD138 and uses thereof |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| TWI888665B (zh) | 2020-11-04 | 2025-07-01 | 美商建南德克公司 | 抗cd20/抗cd3雙特異性抗體之皮下給藥 |
| US12351643B2 (en) | 2020-11-04 | 2025-07-08 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech Inc | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| GB202313214D0 (en) * | 2023-08-30 | 2023-10-11 | Iksuda Therapeutics Ltd | Co-administration of antibody-drug conjugate |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4761111A (en) | 1981-09-18 | 1988-08-02 | Brown Andrew M | Automobile lifting and towing equipment |
| US4418064A (en) | 1982-09-29 | 1983-11-29 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5034223A (en) * | 1986-10-09 | 1991-07-23 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| DE3751319T2 (de) | 1986-10-09 | 1996-02-29 | Neorx Corp | VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN. |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5612016A (en) * | 1988-04-01 | 1997-03-18 | Immunomedics, Inc. | Conjugates of antibodies and bifunctional ligands |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| WO1991016324A1 (en) | 1990-04-25 | 1991-10-31 | The Upjohn Company | Novel cc-1065 analogs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5998656A (en) | 1991-09-23 | 1999-12-07 | Florida State University | C10 tricyclic taxanes |
| US6080777A (en) | 1992-01-31 | 2000-06-27 | The Trustees Of Columbia University In The City Of New York | Taxol as a radiation sensitizer |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5703247A (en) | 1993-03-11 | 1997-12-30 | Virginia Tech Intellectual Properties, Inc. | 2-Debenzoyl-2-acyl taxol derivatives and methods for making same |
| US5475011A (en) | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5763477A (en) | 1994-07-22 | 1998-06-09 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III |
| EP0815096A4 (en) | 1995-03-10 | 1998-07-08 | Hauser Chemical Res Inc | EPOXIDE OF CEPHALOMANNIN, ITS ANALOGS, AND PROCESS FOR PREPARING THE SAME |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| CA2388063C (en) | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| CA2455365C (en) * | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
| EP1507557A4 (en) | 2002-04-23 | 2006-06-14 | Meir Strahilevitz | METHODS AND DEVICES FOR TARGETING A SITE IN A MAMMAL AND DETERMINING CHEMICAL SPECIES FROM A MAMMAL |
| TWI438010B (zh) | 2002-05-02 | 2014-05-21 | Wyeth Corp | 卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物 |
| US6596757B1 (en) | 2002-05-14 | 2003-07-22 | Immunogen Inc. | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
| US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| PL224786B1 (pl) | 2003-01-22 | 2017-01-31 | Glycart Biotechnology Ag | Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza |
| CA2525029A1 (en) | 2003-05-02 | 2004-11-18 | Health Research, Inc. | Use of jag2 expression in diagnosis of plasma cell disorders |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| ATE496944T1 (de) | 2003-07-21 | 2011-02-15 | Immunogen Inc | Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| BRPI0608175A2 (pt) | 2005-04-15 | 2009-11-10 | Immunogen Inc | método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides |
| EP1963370A1 (en) | 2005-12-06 | 2008-09-03 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
| WO2007144046A2 (de) | 2006-05-03 | 2007-12-21 | Elke Pogge Von Strandmann | Mittel zur behandlung von malignen erkrankungen |
-
2008
- 2008-12-23 JP JP2010540130A patent/JP2011507933A/ja active Pending
- 2008-12-23 US US12/342,180 patent/US9011864B2/en not_active Expired - Fee Related
- 2008-12-23 WO PCT/EP2008/068268 patent/WO2009080831A1/en not_active Ceased
- 2008-12-23 EP EP08864283A patent/EP2238169A1/en not_active Ceased
- 2008-12-23 AR ARP080105722A patent/AR069979A1/es unknown
- 2008-12-24 TW TW097150429A patent/TWI524897B/zh not_active IP Right Cessation
-
2014
- 2014-11-28 JP JP2014241327A patent/JP2015038158A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507933A5 (OSRAM) | ||
| Wang et al. | Biomedical metal–organic framework materials: perspectives and challenges | |
| AU2021282425B2 (en) | Bioorthogonal compositions | |
| US11730765B2 (en) | Platelet compositions and methods for the delivery of therapeutic agents | |
| JP2005535606A5 (OSRAM) | ||
| JP2021175754A (ja) | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ | |
| Wu et al. | Hepatocellular carcinoma-targeted nanoparticles for cancer therapy | |
| Li et al. | PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation | |
| JP2018035162A5 (OSRAM) | ||
| CN112675311A (zh) | 18/19f标记的psma靶向诊疗一体化小分子药物偶联物、制备方法及其应用 | |
| JP2011505371A5 (OSRAM) | ||
| WO2017063542A1 (zh) | 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途 | |
| Hunt | Precision targeting of intraperitoneal tumors with peptideguided nanocarriers | |
| JP2015515974A5 (OSRAM) | ||
| CN101537015B (zh) | 碳纳米管在制备抗肿瘤免疫治疗药物的免疫促进剂中的应用 | |
| US20250049936A1 (en) | Bioorthogonal compositions | |
| Luderer | Development of Novel Tumor-Targeted Compounds for Boron Neutron Capture Therapy | |
| Tiersten et al. | Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer | |
| RU2465924C2 (ru) | Способ лечения рака молочной железы | |
| JP2010521488A5 (OSRAM) | ||
| Moorthy et al. | Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer | |
| KR20210106197A (ko) | EGFR과 Her2 발현 암세포를 타겟으로 하는 항체-약물 중합체 개발 | |
| Nahar et al. | Tenofovir Cons the Kidneys: A Case of Acquired Fanconi | |
| CN118743670A (zh) | 一种用于锰免疗法的超分子水凝胶及其制备方法和应用 | |
| Bitran et al. | TANDEM HIGH DOSE CHEMOTHERAPY (INTENSD7ICATION) SUPPORTED BY HEMATOPOHCTIC PROGENITOR CELLS IN METASTATIC BREAST CANCER: A PHASE II STUDY |